Aptevo Therapeutics reported a net loss of $6.5 million for the quarter ended September 30, 2026, and a net loss attributable to common stockholders of $9.3 million after accounting for a $2.8 million deemed dividend. The company's cash position decreased significantly from $21.6 million at the end of 2025 to $8.3 million as of September 30, 2026, primarily due to $19.1 million used in operating activities.
Aptevo Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided a business update on its clinical pipeline. The company highlighted a 79% remission rate for its lead candidate mipletamig in high-risk TP53-mutated AML patients, which is nearly double the historical benchmark for standard-of-care treatments.
“We are entering an exciting period for Aptevo, with growing clinical evidence that reinforces our confidence in mipletamig and meaningful progress across our broader pipeline. We are seeing strong clinical activity in patients with some of the most difficult-to-treat forms of AML, patients advancing to potentially curative stem cell transplantation, and important improvements in tolerability.”
Jeff Lamothe, President and Chief Executive Officer of Aptevo
“As we approach important clinical and development milestones, we believe Aptevo is increasingly well positioned to translate the strength of our science into meaningful opportunities for patients and long-term value for shareholders.”
Jeff Lamothe, President and Chief Executive Officer of Aptevo
Aptevo Therapeutics entered into warrant inducement agreements resulting in the cash exercise of existing warrants for 2,777,778 shares at a reduced price of $1.08 per share. The company received $3.0 million in gross proceeds and issued new 'reload' warrants for up to 13,888,890 additional shares to the participating holders. Proceeds will be used for working capital and general corporate purposes.
Aptevo Therapeutics presented new preclinical data for its multispecific platform candidates APVO451, APVO452, and APVO711 at the SITC 2026 Annual Meeting. The data demonstrated the molecules' ability to activate immune pathways and promote tumor-cell killing even under immunosuppressive conditions typical of solid tumors. These findings support the continued development of the company's portfolio of CD40-stimulating cancer immunotherapies.
Aptevo Therapeutics announced a clinical milestone for mipletamig in frontline AML, achieving a substantial reduction in infusion-related reactions (IRRs) through a refined priming-dose regimen. This optimization, identified through FDA discussions, improves patient tolerability in the ongoing RAINIER study as the company prepares for Phase 2 development.
“We have made substantial progress in improving mipletamig’s tolerability for patients with frontline AML. Mipletamig has demonstrated a differentiated safety and tolerability profile, and successive refinements to the priming-dose regimen have substantially reduced the occurrence of infusion-related reactions. Reducing these reactions matters to patients: it has the potential to make treatment easier to tolerate and limit complications that can disrupt care. These findings are an important part of our preparations for the next stage of clinical development.”
Dirk Huebner, M.D., Chief Medical Officer of Aptevo Therapeutics
Aptevo Therapeutics filed a prospectus supplement to its existing at-the-market (ATM) offering agreement with Roth Capital Partners, allowing for the potential sale of up to $2.3 million in common stock. The company disclosed that it has already raised $11.8 million in gross proceeds through the sale of 303,157 shares under the program to date.
Aptevo Therapeutics reported clinical data from its Phase 1b RAINIER trial showing that 21% of frontline AML patients treated with mipletamig combination therapy advanced to potentially curative stem cell transplants. This transplant rate compares favorably to historical standard-of-care results (0.7% in the VIALE-A trial) for patients initially deemed unfit for intensive chemotherapy. The company expects to conclude dose optimization by year-end and initiate a Phase 2 trial in the first half of 2027.
Aptevo Therapeutics entered into Amendment No. 6 to its Rights Agreement, extending the expiration date of its shareholder rights plan (poison pill) to October 23, 2027. The amendment also adjusted the purchase price for the contingent preferred stock rights to $14.56 per one one-thousandth of a share.